BioMed Research International

BioMed Research International / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 941647 |

Anna Kuna, Michal Gajewski, Beata Szostakowska, Waclaw L. Nahorski, Przemyslaw Myjak, Joanna Stanczak, "Imported Malaria in the Material of the Institute of Maritime and Tropical Medicine: A Review of 82 Patients in the Years 2002–2014", BioMed Research International, vol. 2015, Article ID 941647, 8 pages, 2015.

Imported Malaria in the Material of the Institute of Maritime and Tropical Medicine: A Review of 82 Patients in the Years 2002–2014

Academic Editor: Aparup Das
Received08 Jul 2015
Accepted30 Aug 2015
Published16 Sep 2015


Malaria is, along with tuberculosis and HIV/AIDS, one of the three most dangerous infectious diseases in the world. In the absence of native cases since 1963, malaria has remained in Poland an exclusively imported disease, mainly occurring in people travelling to tropical and subtropical areas for professional reasons. The aim of this study was the epidemiological and clinical analysis of 82 patients admitted to the University Center for Maritime and Tropical Medicine (UCMTM), Gdynia, Poland, with a diagnosis of malaria between 2002 and 2014. The “typical” patient with malaria was male, middle-aged, returned from Africa within the preceding 4 weeks, had not used appropriate chemoprophylaxis, and had not applied nonpharmacological methods of prophylaxis, except for window insect screens. P. falciparum was the most frequent species. The most common symptoms included fever, shivers and intensive sweating, thrombocytopenia, elevated creatinine, LDH, D-dimers and CRP, hepatomegaly, and splenomegaly. Within the analyzed group, severe malaria according to WHO standards was diagnosed in 20.7% of patients. Our report presents analysis of the largest series of patients treated for imported malaria in Poland.

1. Introduction

Malaria is, along with tuberculosis and HIV/AIDS, one of the three most dangerous infectious diseases in the world. It is transmitted by the Anopheles mosquitoes in over 100 countries. The population at risk represents 3.2 billion (half of the world population) people, of whom 1.2 billion are at high risk. In 2013, 198 million cases of malaria were globally noted and led to 584,000 deaths of which 78% were children under five years of age [1]. In the absence of native cases since 1963, malaria has remained in Poland an exclusively imported disease [2]. Fifty cases are annually reported in Poland, while 12000–15000 cases are reported each year in the whole European Union [3]. Annually, 10–15 million people travel from Europe to the regions endemic for malaria. The popularity of exotic travels has also been continuously on the rise in Poland, but there is no precise data regarding the number of people travelling to the areas endemic for malaria. In 2013, 3.4 billion people were living in the regions where the disease occurs. The greatest morbidity and mortality have been recorded in the sub-Saharan Africa and 90% of malaria-related deaths are noted in this region [4]. In Europe, many cases of imported malaria have been recorded in people visiting friends and relatives (VFR) living in endemic areas. The Polish society is rather homogenous and the VFR group is not numerous. Malaria infections mainly occur in people traveling to tropical and subtropical areas for professional reasons (mainly missionaries as well as contract employees in Africa) and for tourism. These groups present high reluctance towards pharmacologic malaria prevention measures and, to some extent, towards nonpharmacological methods preventing mosquito bites. The abovementioned facts, combined with the delay in diagnosis and the implementation of treatment, frequently result in infected patients being admitted to hospital in advanced stages of the disease [5]. For this reason, the malaria mortality rate is several times higher in Poland compared to other European countries [2].

The aim of this study was the epidemiological and clinical analysis of patients admitted to the University Center for Maritime and Tropical Medicine (UCMTM), Gdynia, Poland, with a diagnosis of malaria between 2002 and 2014, considering the prophylaxis used, clinical symptoms at admittance and the time of their persistence prior to adequate diagnosis, and abnormalities in clinical examination and laboratory results, as well as applied treatment and its effectiveness.

2. Material and Methods

A retrospective audit of medical records of patients treated for malaria in UCMTM in the years 2002–2014 was undertaken. The data of 82 patients was collected from the medical records archived in the hospital (clinic) and the Department of Tropical Parasitology (results of parasitological examination). The diagnosis of malaria was based on clinical symptoms, the epidemiological (travel) history and the positive results of microscopic examination of the Giemsa-stained thick and thin blood smears (“gold standard”), the rapid diagnostic tests (RDTs), and PCR assay. All patients diagnosed with malaria were hospitalized: there was no case of outpatient treatment. RDTs (OptiMAL-IT, Bio-Rad) were performed at admittance as accessory tests for quick diagnosis, especially on nonworking days when the obtaining result of the microscopic examination was delayed. The nested-PCR with species-specific primers was used to differentiate Plasmodium species when microscopic examination result was inconclusive or in cases when malaria was suspected in spite of negative microscopic examination results [6, 7]. The demographic, clinical, and laboratory data was entered into a standardized data collection form and entered into an anonymous database.

Ethical Approval. The research was conducted in accordance with the Declaration of Helsinki. The approval number NKBBN/33/2015 of the Independent Bioethics Commission for Research of the Medical University of Gdansk has been obtained for the research.

3. Results

Between 2002 and 2014, 82 patients were admitted to UCMTM with malaria. Among them, 11 were female (13.4%) and 71 male (86.6%). The average age was 39.9 years, ranging between 11 and 70 years. The length of hospitalization was 3 to 44 days, 11.4 days on average. Patients returned mainly from Africa (64 cases), Asia (10 cases), and Central and Southern America (7 cases). Details are presented in Table 1.

Continent/% Number of persons from various countries

Africa64/75.3Nigeria, 11; Ghana, 4; Cameroon, 4; Sudan, 4; Kenya, 3; Angola, 2; Mali, 2; Sierra Leone, 2; Ivory Coast, 2; Congo, 2; RCA, 2; Uganda, 2; Burkina Faso, 1; Chad, 1; Ethiopia, 1; Guinea, 1; Madagascar, 1; Malawi, 1; Mozambique, 1; Senegal, 1; Tanzania, 1;
Africa: travel through multiple countries, 15

Central and Southern America7/8.2Venezuela, 2; Brazil, 1; French Guiana, 2; Peru, 1;
travel through multiple countries, 1

Asia10/12.2India, 6; Indonesia, 2; Afghanistan, 1; multiple countries, 1

No data1/1.2

: number of persons.

The average time of the sojourn (in weeks) in the area endemic for malaria was 59.9 weeks, ranging between 0.5 weeks and 520 weeks (10 years).

Professional duties were declared as the purpose of travel in 37 cases and private matters in 28 cases and 17 patients did not declare the reason for travel. The details concerning purpose of travel are presented in Table 2.

Purpose of travelDetails of sojourn%

DutyMissionaries9 10.9
Sailors, oil platform employees9 10.9
Contract workers (speleologists, drillers, and heavy equipment operators)6 7.3

PrivateVFR2 2.4


: number of persons.

The average time between the date of return from area endemic for malaria and the onset of symptoms was 16.5 days, ranging between 0 (“directly from the airport”) and 164 days.

The pharmacological prophylaxis was correctly used (appropriate drug and dosage) in 14 (17%) patients. The usage of window mosquito screens, the common equipment in the tropic, was the most popular among nonpharmacologic methods. As many as 14 patients did not use any prophylaxis against malaria. The details of prophylaxis used are presented in Tables 3(a) and 3(b).


Type of prophylaxisDetails%

ChemoprophylaxisCorrectly usedMefloquine, later followed by atovaquone + proguanil22.4
Atovaquone + proguanil910.9
Atovaquone + proguanil, later followed by doxycycline11.2
No chemoprophylaxis4757.3
Medication taken irregularly67.3
Inappropriate medication22.4
No data1619.5

Window insect screensDeclared usage3949.6
Not used2735.4

Mosquito bed netsDeclared usage33.7
Not used6376.8

RepellentsDeclared usage2024.4
Not used4656.1

InsecticidesDeclared usage56.1
Not used6174.4

: number of persons.

No nonpharmacologic prophylaxisWindow insect screenMosquito bed netInsect repellentsInsecticides%

Regular chemoprophylaxisX33.7

Medication taken irregularlyX33.7

Inappropriate medicationX11.2

No medicationX1417.1

: number of persons.

A history of malaria in the past was reported by 25 patients. There is no data concerning the species of the previous infections. Among the 25 patients, 13 were diagnosed with P. falciparum and 8 with P. vivax, 1 was diagnosed with P. ovale and 1 with P. malariae, and 2 had a mixed infection with P. falciparum and P. vivax. In further 4 cases of P. falciparum, 1 case of P. vivax, 1 case of mixed P. vivax and P. ovale infection, and all cases without identification of species, it is unknown whether the patients had malaria in the past. In all these cases, we cannot completely exclude the possibility that the observed infection was a relapse.

The average time between the onset of symptoms and the correct diagnosis was 6.6 days (1 day to 28 days).

Prior to admittance, the majority of the patients reported fever (91.5%), shivers (42.7%), increased sweating (22%), weakness (18.3%), influenza-like symptoms (18.3%), and headaches (18.3%). The summary of all reported symptoms is presented in Table 4.

Symptoms and diagnoses prior to admittance, at least one from the group present%

Fever75 91.5
Shivers35 42.7
Increased sweating18 22
Weakness, influenza-like symptoms (musculoskeletal pains, malaise), and headaches15 18.3
Diarrhea9 11
Vomits7 8.5
Nausea5 6.1
Psychomotoric retardation, confusion4 4.9
Dyspnea, cough, oliguria or anuria, and abdominal pains3 3.6
Weight loss, shock, respiratory infection, and loss of appetite2 2.4
Icterus, hepatic injury, DIC, miscarriage, thrombocytopenia, anemia, and middle ear infection 11.2

: number of persons.

62 patients received no treatment before hospitalization. There is no data concerning 4 patients. Three patients initiated correct antimalarial treatment (appropriate drug and dosage) on their own and 11 used it incorrectly. These medications were obtained by the patients’ own means. Antibiotics (at least one) were taken by 13 persons.

During the hospitalization, various clinical symptoms were observed (Table 5) and, in the cases of preceding hospitalization in other hospitals, initial diagnoses were known. Most frequent findings included fever (91.5%), hepatomegaly (63.4%), shivers (62.2%), anemia (62.2%), splenomegaly (54.9%), and increased sweating (48.8%). The oliguria or anuria was observed in 7 patients and 4 of them required hemodialysis with subsequent full recovery of renal function (3 cases) and death in one case.

Symptoms and diagnoses during hospitalization%

Increased sweating4048.8
Fever over 39°C3947.6
Fever 38-39°C3643.9
Icterus31 37.8
Headaches29 35.4
Renal failure21 25.6
Muscle pains17 20.7
Consciousness disorders17 20.7
Nausea11 13.4
Abdominal pains911
Shock9 11
Vomits8 9.8
Hearing loss6 7.3
Respiratory failure 4 4.9
Pulmonary edema1 1.2

Numerous various alterations were observed in laboratory test results; they are presented in Table 6.

Laboratory parameterUnitNormAverage valueRange of valuesMean

Hemoglobin at admittanceg/dL11.5–16.513.48 6.3–16.612
Hemoglobin, lowest concentration11.876.3–17.213.6
Creatinine (highest level)mg/dL0.5–0.91.660.57–191.1
GPT at admittanceU/L<3350.769–19144
GPT highest value89.169–59654
GOT at admittanceU/L<3252.1911–25138
GOT highest value81.5111–84243

In 79 out of 82 patients, the species of Plasmodium was determined. P. falciparum was detected in 52 people, P. vivax in 23 patients, P. ovale in 4 patients, and P. malariae in 4 patients. Among these patients, 4 had a mixed infection (P. falciparum + P. vivax: 2 patients; P. vivax + P. ovale: 2 patients). Three of the patients with mixed infections (2 with P. vivax and P. falciparum; 1 with P. vivax and P. ovale) visited only one location during their travel; the details regarding travel destination of one of the patients with P. ovale and P. vivax infection are unknown. The average parasitemia was 3.16% (0.01 to 37%) and it exceeded 2% in 23 people. On average, the presence of parasites in blood was observed for 2.9 days (1 day to 7 days).

The standard diagnostic method for diagnosis and differentiation of Plasmodium species was the microscopic examination of thick and thin blood films. RDTs were performed in 47 patients; negative results were obtained in 6 cases. Species-specific PCR assays were performed in 38 patients.

In abdominal sonography, hepatomegaly was observed in 50 patients and splenomegaly in 44 people. Among them, 34 patients had the enlargement of both organs. The chest X-ray revealed pneumonia in 11 patients, pulmonary congestion in 7 patients, atelectasis in 4 patients, hydrothorax in 5 patients, and BOOP in 1 patient. The head CT scan was not routinely performed, it was normal in 1 patient, and it revealed massive ischemic lesions and brain edema in another patient.

The patients received various treatment regimens, usually quinine (51 patients, 64.3%) and artemisinin derivates (23 people, 28%). All patients were treated after admission to the hospital. The details of therapy are summarized in Table 7.

MedicationRoute of administration%

Quinine in totali.v./p.o.5162.2

i.v. only2125.6
p.o. only 3036.6
Initially i.v., followed by p.o.2631.7

Quinine + doxycycline4656.1

Quinine + clindamycin44.9

Quinine + doxycycline + clindamycin22.4

Artemisinin derivates in totali.v./i.m./p.o.2328


Artemether + lumefantrinep.o.78.5



Sulfadoxine + pyrimethaminep.o.11.2


Atovaquone/proguanil as adjuvant to ACTsp.o.56.1

Atovaquone/proguanil + doxycycline + primaquinep.o.11.2

Atovaquone/proguanil + quinine + doxycyclinep.o.11.2

Atovaquone/proguanil + artemether/lumefantrinep.o.11.2

: number of persons.

The treatment failure was observed in one patient: death occurred on the 4th day of hospitalization. One of the patients with tertian malaria did not take primaquine in spite of receiving such recommendation. Moreover, one patient did not receive primaquine in spite of P. vivax infection for unknown reason. One patient received primaquine in spite of being infected with P. malariae and terminated the treatment after receiving the result of PCR test (the species was not initially determined in peripheral blood smear).

In cases of severe course and concurrent superinfections, additional drugs were used including mannitol (18.3%), 1 additional antibiotic (34.1%), 2 antibiotics (3.7%), 3 antibiotics (6.1%), corticosteroids (24.4%), and catecholamines (7.3%).

In 3 patients, additional parasitic diseases were diagnosed (schistosomiasis: 1 patient; Blastocystis hominis: 1 patient; Giardia intestinalis: 1 patient). Nine patients were diagnosed with pneumonia, 3 with a urinary tract infection, and 27 with a hepatic injury; 1 was diagnosed with brain infarction; 5 were diagnosed with pulmonary embolism; 1 was diagnosed with minimal consciousness, splenic rupture, and vast ischemic lesions in the brain; 3 were diagnosed with respiratory failure, 10 with acute renal failure, 59 with thrombocytopenia, 3 with purpura, and 4 with DIC; 1 was diagnosed with brain edema and 1 with ARDS.

All patients were recommended a follow-up hospitalization one month after the discharge. 85% of the patients followed this recommendation. The relapse was observed in the 3 cases of P. vivax infections.

4. Discussion

The majority of the patients hospitalized in UCMTM due to malaria were males (86,6%) returning from Africa (75.3%). The geographic region of origin of the disease is consistent with the results of other studies: one of the authors demonstrated that 1 in 5 patients with fever returning from sub-Saharan Africa had malaria [8]. The percentage is much lower (maybe 1/100) in patients with malaise returning from Asia and Southern America.

37 patients travelled for professional reasons and 26 for private ones. The majority of patients travelled for professional reasons (45%). The declared small number of VFRs (2.4%) is probably a result of the homogeneity of Polish society and the low percentage of immigrants living in Poland. The relatively low percentage of missionaries diagnosed with malaria compared to their number of hospitalization cases after sojourn in tropic is probably a result of their self-treatment with antimalarial medication brought by them from Africa.

A very small number of patients used chemoprophylaxis; only 14 of them used an appropriate drug correctly. In general, European travelers rarely use malaria prophylaxis. The data from TropNet Europe indicates that only 60.4% of the travelers used preventive measures against malaria in the years 1999-2000. The minority of patients used an appropriate drug correctly. In our study, this rate is much lower (17%). Moreover, a significant part of the travelers stay in endemic areas for many years (missionaries in particular) and recommendations for prophylaxis are different for this group [9].

The majority of falciparum malaria occurs within the 3 months after return, but in some patients the disease is diagnosed within up to one year, and, in the case of non-falciparum malaria, even several years after return [10].

In the examined group, the average time from the return from endemic area to the onset of symptoms was 16.5 days. This time was considerably shorter for P. falciparum (7.8 days) and for P. vivax it was 35.8 days. The longest time (164 days) was recorded in a soldier returning from Afghanistan infected with P. vivax who had been taking chemoprophylaxis (atovaquone/proguanil) correctly. The patient stayed in Afghanistan for 8 months. One month before the return, he was treated for malaria; he did not have any documentation of the treatment. Four days before admittance, episodes of high fever and symptoms of upper respiratory tract infection occurred. At admittance, the patient presented dehydration, hepatosplenomegaly, thrombocytopenia, elevated bilirubin, CRP, and D-dimer concentration. RDT, blood smear, and PCR were positive for P. vivax. Treatment with quinine and doxycycline was started. After one week of treatment, primaquine was introduced and the patient was discharged home in good condition. During the follow-up hospitalization one month later, no abnormalities were observed and the blood smears for malaria were negative.

Among our patients, the average time between the onset of symptoms and the correct diagnosis was 7.7 days (1 day to 28 days) for falciparum malaria, for P. vivax it was 5.75 days (1 day to 22 days), for P. ovale 6.5 days (5 to 8 days), and for P. malariae 12.5 days (5 to 21 days). In the cases of mixed infections, the average time before the diagnosis was 2.5 days for falciparum + vivax infections and 14 days for vivax + ovale infections. Only one fatal case among our center’s malaria patients during 12 years of observation proves the high experience of staff working in our hospital in the field of tropical medicine, good diagnostic resources, and the vigilance of the patients themselves who frequently come directly to the hospital suspecting malaria in them.

The diagnosis of malaria in nonendemic countries remains a challenge; therefore, the doctors’ awareness and ability to select patients presenting high risk of Plasmodium infection should diminish the risk of severe course of the disease and death [11]. On the other hand, the lack of inclusion of malaria in differential diagnosis in patients with fever returning from tropical areas and the low awareness of the necessity of fast diagnosis may lead to unacceptable delay in treatment introduction [12]. The only death in our center was a result of the delayed diagnosis and the lack of prophylaxis against malaria: the patient stayed for 5 days in Senegal, presented influenza-like symptoms after return to Poland for over 20 days, and was treated by his general practitioner for presumed bronchitis. At admittance to the hospital, falciparum malaria was diagnosed with parasitemia 7.4% and multiorgan failure. Despite the immediate introduction of antimalarial treatment under the conditions of intensive care unit and the initiation of hemodialysis due to anuria, the patient died on the 7th day. Ironically, the postmortem examination revealed that the Plasmodium species was susceptible to all available antimalarial agents, including chloroquine.

As of now, the efforts to create standards for malaria diagnosis based on clinical symptoms have failed [13]. Among English patients, high frequency of thrombocytopenia and hyperbilirubinemia was demonstrated [14]; in the Swiss series, thrombocytopenia had posttest probability of 82% and clinically enlarged spleen 85% and these two factors combined 98% [15]. In the case of our center, the “typical” patient with malaria was male (86.6%), middle-aged (average 38.9 years) who returned from Africa (75.3%) in the preceding 4 weeks, had not used appropriate chemoprophylaxis, and had not applied nonpharmacological methods of prophylaxis, except for window insect screens. At admittance, the patient presented with fever (91%), shivers (42%), and intensive sweating (22%). Laboratory results were remarkable for thrombocytopenia (83 G/L on average), elevated creatinine (1.66 mg/dL on average), LDH (759 UL/on average), D-dimers (3062 ng/mL on average), and CRP (19.37 mg/L on average). The results of imaging scans more often revealed hepatomegaly (63%) compared to splenomegaly (55%). In the analyzed group, severe malaria according to WHO standards was diagnosed in 17 patients (20.7%) after inclusion of parasitemia over 10% as one of the markers of this form of disease [16]. With the sometimes used criterion of parasitemia exceeding 2% for patients with severe malaria in nonendemic countries, this group would be expanded to 25 (30.4%). The most frequent form in the analyzed group was renal failure and hyperbilirubinemia. The WHO criteria for diagnosis of severe malaria were used for all Plasmodium species.

In the available literature, dominating forms of severe malaria include cerebral malaria, renal failure, and acute lung injury (ARDS) [16].

DIC and shock are less frequent and rarely exist as an isolated disorder. Icterus (due to hemolysis) and parasitemia over 2% are the prognostic factors of development of severe malaria in spite of initially good condition of the patient [17].

In the analyzed group, we did not observe significant increase in the number of falciparum cases and a decrease in number of tertian malaria cases was observed, contradicting studies from many other centers in nonendemic countries [18]. In each of the years, at least 10% of cases were tertian malaria, sometimes in its severe form. Reports on severe course of vivax cases and possible severe course of ovale and malariae infections suggest that such course may be more frequent than previously thought and that describing non-falciparum malaria as “mild” may be confusing [19]. In the analyzed group, we classified only one case of vivax infection as severe which constitutes 4% of all cases of infection with this species.

As far as the specific groups of children and pregnant women are concerned, only 2 persons in the analyzed group were minors (11 and 17 years) and only one patient was pregnant; therefore, no conclusions may be drawn from analysis of such small groups.

Various combinations of drugs were used in our hospital. No official antimalarial drug policy currently exists in Poland. National guidelines are currently under preparation; therefore, the choice of medication was mainly based on the WHO guidelines combined with the individual experience and preference of the treating physician and the head of the department. Since 2012, import of artesunate in the parenteral form has become possible which, combined with current recommendations and difficulties in quinine acquisition in Europe, motivated us to change methods of treatment in our malaria patients. Average PCT for treatment with artemisinin derivates was 2.17 days (1 day to 5 days) compared to 3.93 (1 day to 7 days) days for quinine. Along with obvious advantages of artemisinin treatment proven in multiple clinical trials, a very important factor is the convenience of drug application for the patient and staff. Among 23 patients who received ACTs, hemolytic anemia with a decrease in hemoglobin level to 8.3 g/dL was observed in only one patient in the 3rd week after treatment and it later resolved spontaneously.

The climate conditions (the number of warm days per year) are currently not favorable for the reintroduction of malaria in Poland in spite of the presence of its vector, the Anopheles mosquito [2]. Although there are alarming reports from Greece and Spain where cases of domestic malaria cases have recently been observed, the national epidemiological surveillance has prevented reintroduction of the disease to Poland for the last decades.

5. Conclusions

Our report presents analysis of the largest series of patients treated for imported malaria in Poland. Although interest in exotic travels increases in our country, usage of appropriate prophylaxis against malaria remains low. The knowledge of malaria symptoms by physicians and obtaining thorough medical and travel history as well as taking malaria into consideration in the differential diagnosis remain crucial for correct diagnosis and may help avoid unnecessary and potentially fatal delay in the introduction of appropriate treatment.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  2. J. Knap and P. Myjak, Eds., Malaria w Polsce i na Świecie, Wczoraj i Dziś, Alfa Medica Press, Bielsko-Biała, Poland, 2009.
  3. R. Romi, D. Boccolini, S. D'Amato et al., “Incidence of malaria and risk factors in Italian travelers to malaria endemic countries,” Travel Medicine and Infectious Disease, vol. 8, no. 3, pp. 144–154, 2010. View at: Publisher Site | Google Scholar
  4. World Health Organization, World Malaria Report 2011, World Health Organization (WHO), Geneva, Switzerland, 2011.
  5. L. C. Santos, C. F. Abreu, S. M. Xerinda, M. Tavares, R. Lucas, and A. C. Sarmento, “Severe imported malaria in an intensive care unit: a review of 59 cases,” Malaria Journal, vol. 11, article 96, 2012. View at: Publisher Site | Google Scholar
  6. B. Singh, A. Bobogare, J. Cox-Singh, G. Snounou, M. S. Abdullah, and H. A. Rahman, “A genus- and species-specific nested polymerase chain reaction malaria detection assay for epidemiologic studies,” American Journal of Tropical Medicine and Hygiene, vol. 60, no. 4, pp. 687–692, 1999. View at: Google Scholar
  7. P. Myjak, W. Nahorski, N. Pieniazek, and H. Pietkiewicz, “Usefulness of PCR for diagnosis of imported malaria in Poland,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 21, no. 3, pp. 215–218, 2002. View at: Publisher Site | Google Scholar
  8. C. Nic Fhogartaigh, H. Hughes, M. Armstrong et al., “Falciparum malaria as a cause of fever in adult travellers returning to the United Kingdom: observational study of risk by geographical area,” QJM: An International Journal of Medicine, vol. 101, no. 8, pp. 649–656, 2008. View at: Publisher Site | Google Scholar
  9. T. Jelinek, C. Schulte, R. Behrens et al., “Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases,” Clinical Infectious Diseases, vol. 34, no. 5, pp. 572–576, 2002. View at: Publisher Site | Google Scholar
  10. E. Bottieau, J. Clerinx, E. Van Den Enden et al., “Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center,” The American Journal of Tropical Medicine and Hygiene, vol. 75, pp. 133–138, 2006. View at: Google Scholar
  11. M. Jensenius, E. J. Rønning, H. Blystad et al., “Low frequency of complications in imported falciparum malaria: a review of 222 cases in south-eastern Norway,” Scandinavian Journal of Infectious Diseases, vol. 31, no. 1, pp. 73–78, 1999. View at: Publisher Site | Google Scholar
  12. R. A. Winters and H. W. Murray, “Malaria—the mime revisited: Fifteen more years of experience at a New York City teaching hospital,” American Journal of Medicine, vol. 93, no. 3, pp. 243–246, 1992. View at: Publisher Site | Google Scholar
  13. D. Chandramohan, S. Jaffar, and B. M. Greenwood, “Use of clinical algorithms for diagnosing malaria,” Tropical Medicine & International Health, vol. 7, no. 1, pp. 45–52, 2002. View at: Publisher Site | Google Scholar
  14. J. F. Doherty, A. D. Grant, and A. D. M. Bryceson, “Fever as the presenting complaint of travellers returning from the tropics,” Quarterly Journal of Medicine, vol. 88, no. 4, pp. 277–281, 1995. View at: Google Scholar
  15. V. D'Acremont, P. Landry, I. Mueller, A. Pecoud, and B. Genton, “Clinical and laboratory predictors of imported malaria in an outpatients setting: an aid to medical decision making in returning travellers with fever,” The American Journal of Tropical Medicine and Hygiene, vol. 66, no. 5, pp. 481–486, 2002. View at: Google Scholar
  16. World Health Organization, “Severe malaria,” Tropical Medicine & International Health, vol. 19, supplement 1, pp. 7–131, 2014. View at: Google Scholar
  17. C. J. M. Whitty, P. L. Chiodini, and D. G. Lalloo, “Investigation and treatment of imported malaria in non-endemic countries,” British Medical Journal, vol. 346, no. 7909, Article ID f2900, 2013. View at: Publisher Site | Google Scholar
  18. Health Protection Agency, “Malaria imported into the United Kingdom in 2011: implications for those advising travelers,” Health Protection Report 6, Health Protection Agency, London, UK, 2012. View at: Google Scholar
  19. D. K. Kochar, A. Das, S. K. Kochar et al., “Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India,” The American Journal of Tropical Medicine and Hygiene, vol. 80, no. 2, pp. 194–198, 2009. View at: Google Scholar

Copyright © 2015 Anna Kuna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.